share_log

Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025

Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025

猎户座公司:截至2025年5月31日猎户座集团执行管理委员会的变动
GlobeNewswire ·  05/07 01:30

ORION CORPORATION
STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS
7 May 2024 at 08.30 EEST
Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025

猎户座公司
证券交易所新闻稿 — 更换董事会/管理层/审计师
2024 年 5 月 7 日美国东部标准时间 08:30
猎户座公司:截至2025年5月31日猎户座集团执行管理委员会的变动

Olli Huotari, Senior Vice President responsible for Corporate Functions organization (including, i.a., Communications, Compliance, Corporate Responsibility, Intellectual Property Rights, Legal Affairs and Public Affairs) of the Orion Group and Secretary to the Board of Directors of Orion Corporation, and a member of the Executive Management Board of the Orion Group has informed the company of his decision to leave Orion. Orion will start a recruiting process of the successor to Olli Huotari. In order to secure a proper transition of responsibilities to his successor, Orion and Huotari have agreed that Huotari will continue in his current positions at Orion (including the membership of the Executive Management Board of the Orion Group) until 31 May 2025, after which he will leave the company.

负责猎户座集团公司职能组织(包括沟通、合规、企业责任、知识产权、法律事务和公共事务)的高级副总裁兼猎户座公司董事会秘书奥利·霍塔里和猎户座集团执行管理委员会成员已通知公司,他决定离开猎户座。猎户座将开始招募奥利·霍塔里继任者。为了确保将责任适当移交给继任者,猎户座和霍塔里已同意,霍塔里将继续担任其目前在猎户座的职位(包括猎户座集团执行管理委员会的成员),直至2025年5月31日,之后他将离开公司。

Olli Huotari has held group-level leadership positions at Orion since 2002.

自2002年以来,奥利·霍塔里一直在猎户座担任集团级领导职务。

President and CEO Liisa Hurme says:

总裁兼首席执行官丽莎·赫尔姆说:

"I want to warmly thank Olli for his great work for Orion. It is of course a pity when such a proficient and experienced leader wants to leave. However, as much as we would like to keep him with the company, we must respect his decision. We are pleased that Olli has agreed to continue working at Orion for a sufficient period in order to ensure a smooth transition of responsibilities and introduction of his successor. This also reflects Olli as a person − he always wants to make sure that the company's interests are taken care of."

“我要衷心感谢奥利为猎户座所做的出色工作。当这样一位熟练和经验丰富的领导者想要离开时,这当然是很可惜的。但是,尽管我们想让他留在公司,但我们必须尊重他的决定。我们很高兴奥利同意继续在猎户座工作一段时间,以确保顺利移交职责和引进继任者。这也反映了奥利作为一个人——他一直想确保公司的利益得到照顾。”

Olli Huotari says:
"I have always appreciated and been very grateful for all the positions and career Orion has offered to me. Orion is a great company with great people. Until the end of May 2025, I will continue working for the company and will do my best so that my successor will have the best possible start in the new position. After that, I will move to the next phase of my life."

奥利·霍塔里说道:
“我一直对猎户座为我提供的所有职位和职业生涯表示赞赏和感激。Orion 是一家拥有优秀人才的优秀公司。在2025年5月底之前,我将继续为公司工作,并将尽我所能,使我的继任者在新职位上有尽可能好的开端。之后,我将进入人生的下一个阶段。”

Orion Corporation

猎户座公司

Liisa Hurme
President and CEO
Terhi Ormio
Vice President, Communications
Liisa Hurme
总裁兼首席执行官
Terhi Ormio
传播副总裁


Contact person:
Liisa Hurme
President and CEO
tel. +358 50 966 2874


联系人:
Liisa Hurme
总裁兼首席执行官
电话:+358 50 966 2874

Contact person for the media:
Terhi Ormio, Vice President, Communications
tel. +358 50 966 4646
terhi.ormio@orion.fi

媒体联系人:
Terhi Ormio,传播副总裁
电话:+358 50 966 4646
terhi.ormio@orion.fi

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland

出版商:
猎户座公司
通信
Orionintie 1A,FI-02200 埃斯波,芬兰

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Orion 是一家全球运营的芬兰制药公司,是幸福的缔造者。我们开发、制造和销售人类和兽药以及活性药物成分。Orion 拥有广泛的专有和仿制药以及消费者健康产品组合。我们药物研发的核心治疗领域是肿瘤学和疼痛。Orion 开发的专有产品用于治疗癌症、神经系统疾病和呼吸系统疾病等。猎户座在2023年的净销售额为11.9亿欧元,截至年底,该公司拥有约3600名员工。猎户座的A股和B股在赫尔辛基纳斯达克上市。


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发